Cogent Biosciences, Inc.
COGT
$34.19
-$0.19-0.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 104.76% | 21.75% | 32.56% | 22.73% | 22.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.94% | 10.53% | 17.39% | 20.08% | 26.63% |
| Operating Income | -34.94% | -10.53% | -17.39% | -20.08% | -26.63% |
| Income Before Tax | -50.89% | -14.58% | -24.73% | -23.37% | -24.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.89% | -14.58% | -24.73% | -23.37% | -24.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.89% | -14.58% | -24.73% | -23.37% | -24.95% |
| EBIT | -34.94% | -10.53% | -17.39% | -20.08% | -26.63% |
| EBITDA | -35.23% | -10.59% | -17.48% | -20.21% | -26.86% |
| EPS Basic | -11.79% | 8.23% | -8.06% | 99.91% | 2.54% |
| Normalized Basic EPS | -11.17% | 8.22% | -8.05% | 99.91% | 8.27% |
| EPS Diluted | -11.79% | 8.23% | -8.06% | 99.91% | 2.54% |
| Normalized Diluted EPS | -11.17% | 8.22% | -8.05% | 99.91% | 8.27% |
| Average Basic Shares Outstanding | 34.97% | 24.83% | 15.42% | 139,706.04% | 28.21% |
| Average Diluted Shares Outstanding | 34.97% | 24.83% | 15.42% | 139,706.04% | 28.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |